<DOC>
	<DOCNO>NCT01528254</DOCNO>
	<brief_summary>The purpose study determine whether initiation vildagliptin plus metformin combination regimen would result durable glycemic control metformin monotherapy treatment-naïve patient T2DM .</brief_summary>
	<brief_title>VERIFY : A Study Compare Combination Regimen With Vildagliptin &amp; Metformin Versus Metformin Treatment-naïve Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 Diabetes Mellitus ( T2DM ) diagnose ≤ 24 month ago glycosylated hemoglobin ( HbA1c ) ≥6.5 % ≤7.5 % Visit 1 Treatmentnaïve . Body mass index ( BMI ) ≥22 ≤40 kg/m2 Visit 1 Pregnant nursing ( lactate ) woman Fasting plasma glucose ( FPG ) ≥ 270 mg/dL ( ≥ 15.0 mmol/L ) Previous current participation vildagliptin clinical study . History hypersensitivity dipeptidyl peptidase4 ( DPP4 ) inhibitor . Concurrent medical condition may interfere interpretation efficacy safety data study . Donation blood significant blood loss equal least one unit blood within past 2 week start study blood transfusion within past 12 week plan regular transfusion study period Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Type 2 Diabetes Mellitus ,</keyword>
	<keyword>Vildagliptin ,</keyword>
	<keyword>Elderly Patients</keyword>
</DOC>